Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1

Newly published abstract regarding dose escalation patients provides key updates including: ≥50% PSA reduction observed across putative therapeutic dose levels ≥2.0 mg/kg – 3 of 3 in Cohort 6...

Related Keywords

United States , Spain , Madrid , John Shen , David Mills , Danielj Oconnor , Karissa Cross , Mike Moyer , Shawn Zhang , Nasdaq , Scripps Research Institute , Globenewswire Inc , European Society Of Medical Oncology , Lifesci Communications , Ambrx Biopharma Inc , Medical Oncology , Key Opinion Leader , First In Human Phase , Chief Executive Officer , Prostate Cancer Poster Session , Prostate Cancer Poster , Basic Science Poster Session , Basic Science Poster , Private Securities Litigation Reform Act , Current Report , Markets ,